FRENCH NEWSPAPER CLAIMS ARMSTRONG ADMITTED EPO USE

Lance Armstrong Tour podium 05

Prestigious French newspaper Le Monde on Friday claimed Lance Armstrong admitted he has taken the performance-enhancing drug erythropoietin (EPO) and other banned substances before being treated for cancer in 1996.

The paper says Armstrong?s former team mate Frankie Andreu and his wife Betsy said under oath at a hearing of a Texan arbitration case between Lance Armstrong and prize money insurance company SCA that they heard Armstrong admit to taking 'EPO, testosterone, growth hormones and cortisone', before he began his treatment for testicular cancer.

"In front of (Motorola team-mate) Frankie Andreu and his wife, who have testified under oath in Dallas, Armstrong said he had taken 'EPO, testosterone, growth hormones and cortisone'," Le Monde reported.

During the court case Armstrong denied making an admission, adding that if Betsy Andreu had testified against him, it's because she hated him and her husband Frankie backed her up to support her.

Le Monde reports: ?McIlvain says (to Lemond) "if I'm asked to take the stand, I'll do it (...) Because I won't lie. You know I was in that room. I heard."

None of the three other witnesses present in Armsttong's hopstial room on October 28, 1996 were asked to testify. They are Armstrong's girlfriend at the time, Lisa Shiels, his long-term and close friend Chris Carmichael and his wife Paige. Neither of the doctors who operated on him were called to the stand either.

Thank you for reading 20 articles this month* Join now for unlimited access

Enjoy your first month for just £1 / $1 / €1

*Read 5 free articles per month without a subscription

Join now for unlimited access

Try first month for just £1 / $1 / €1

Founded in 1891, Cycling Weekly and its team of expert journalists brings cyclists in-depth reviews, extensive coverage of both professional and domestic racing, as well as fitness advice and 'brew a cuppa and put your feet up' features. Cycling Weekly serves its audience across a range of platforms, from good old-fashioned print to online journalism, and video.